Randomization and blinding
NSCLC
RECURRENT DISEASE, NSCLC
Patients were randomized (1:1) in a blinded manner to receive either BAT1706 plus chemotherapy or EU‐bevacizumab plus chemotherapy using the Interactive Web Response System (IWRS). Randomization was stratified by the following factors: stage of NSCLC (recurrent disease of any stage at the time of primary diagnosis, or Stage IV); sex (male or female); and ethnicity (Asian or non‐Asian). Patient numbers were assigned consecutively. Double‐blinding was maintained throughout the study; unblinding was only allowed in cases of an emergency for safety concerns.